Doxorubicin disaccharide analogue: Apoptosis-related improvement of efficacy in vivo

Journal of the National Cancer Institute

Volumn 89, Issue 16, 1997, Pages 1217-1223

  Arcamone, Federico ^a   Animati, Fabio ^a   Berettoni, Marco ^a   Bigioni, Mario ^a   Capranico, Giovanni ^b   Casazza, Anna Maria ^c   Caserini, Claudia ^b   Cipollone, Amalia ^a   De Cesare, Michelandrea ^b   Franciotti, Maurizio ^a   Lombardi, Paolo ^a   Madami, Andrea ^a   Manzini, Stefano ^a   Monteagudo, Edith ^a   Polizzi, Donatella ^b   Pratesi, Graziella ^b   Righetti, Sabina C ^b   Salvatore, Carmela ^a   Supino, Rosanna ^b   Zunino, Franco ^b  

^a Menarini Ricerche SpA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN DERIVATIVE; SABARUBICIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; SOLID TUMOR;

EID: 0030807646     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.16.1217     Document Type: Article

References (23)

1. Arcamone F. Doxorubicin, anticancer antibiotics. New York: Academic Press, 1981.
2. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19:670-86.
3. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des 1992;5:307-17.
4. Di Marco A, Casazza AM, Gambetta R, Supino R, Zunino F. Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives. Cancer Res 1976;36:1962-6.
5. Gresh N, Pullman B, Arcamone F, Menozzi M, Tonani R. Joint experimental and theoretical investigation of the comparative DNA binding affinities of intercalating anthracycline derivatives. Mol Pharmacol 1988;35:251-6.
6. Priebe W, Van NT, Burke TG, Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs 1993;4:37-48.
7. Capranico G, Supino R, Binaschi M, Capolongo L, Grandi M, Suarato A, et al. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol Pharmacol 1994;45: 908-15.
8. Animati F, Berettoni M, Cipollone A, Franciotti M, Lombardi P, Monteagudo E, Arcamone F. New anthracyclinc disaccharides synthesis of L-daunosaminyl-α(1→4)-2-deoxy-L-rham-nosyl and of L-daunosaminyl-α(1→4)-2-deoxy-L-fucosyl daunorubicin analogues. J Chem Soc Perkin Trans I 1996: 1327-9.
9. Smid P, de Ruiter GA, van der Marel GA, Rombouts FM, van Boom JH. Iodorium-ion assisted stereospecific glycosylation synthesis of oligosaccharides containing α(1-4)-linked L-glycopyranosyl units. J Carhohydr Chem 1991; 10:833-49.
10. Kimura Y, Suzuki M, Matsumoto T, Abe R, Terashima S. Novel glycosidation of 4-demethoxyanthracyclines by the use of trimethylsilyl triflate syntheses of optically active 4-demethoxydaunorubicin and 4-demethoxyadriamycin. Bull Chem Soc Jpn 1986;59:423-31.
11. 1H coupling constants. Application to a disaccharide. J Mgn Reson 1991;93:214-7.
12. Homans SW. A molecular mechanical force field for the conformational analysis of oligosaccharides: comparison of theoretical and crystal structures of Manα1-3Manβ1-4G1cNAc. Biochemistry 1990;29:9110-8.
13. Kohn KW. DNA repair: a laboratory manual of research procedures. New York: Marcel Dekker, 1981.
14. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56: 556-62.
15. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 1988;58:109-13.
16. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
17. Mondelli R, Ragg E, Fronza G, Arnone A. Nuclear magnetic resonance conformational study of daunomycin and related antitumor antibiotics in solution. The conformation of ring A. J Chem Soc Perkin Trans II 1987;2:15-26.
18. Cicero DO, Barbato G, Bazzo R. NMR analysis of molecular flexibility in solution: a new method for the study of complex distributions of rapidly exchanging conformations. Application to a 13-residue peptide with an 8-residue loop. J Am Chem Soc 1995;117:1027-33.
19. Pratesi G, Animati F, Arcamone F, Berettoni M, Bigioni M, Cipollone A, et al. Antitumor activity of 7-[L-daunosaminyl-α(1 4(-2-deoxy-α-L-fucosyl]-4-demethoxyadriamicinone (MEN10755) in a panel of human tumor xenografts naturally resistant to doxorubicin. Proc Am Assoc Cancer Res 1996;37:394.
20. Pratesi G, Bigioni M, De Cesare M, Supino R, Zunino F, Animati F, et al. Pharmacological properties of a novel anthracycline aminodisaccharide in human lung and gynecological cancers. Preclinical studies [abstract 135]. In: 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1996.
21. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
22. Borgnetto ME, Zunino F, Tinelli S, Kas E, Capranico G. Drug-specific sites of the topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility. Cancer Res 1996;56:1855-62.
23. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.